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Objective Little is known about persistence of or
recovery from chronic fatigue syndrome/myalgic
encephalomyelitis (CFS/ME) in adolescents. Previous
studies have small sample sizes, short follow-up or have
focused on fatigue rather than CFS/ME or, equivalently,
chronic fatigue, which is disabling. This work aimed to
describe the epidemiology and natural course of CFS/ME
in adolescents aged 13–18 years.
Design Longitudinal follow-up of adolescents enrolled
in the Avon Longitudinal Study of Parents and Children.
Setting Avon, UK.
Participants We identiﬁed adolescents who had
disabling fatigue of >6 months duration without a
known cause at ages 13, 16 and 18 years. We use the
term ‘chronic disabling fatigue’ (CDF) because CFS/ME
was not veriﬁed by clinical diagnosis. We used multiple
imputation to obtain unbiased estimates of prevalence
and persistence.
Results The estimated prevalence of CDF was 1.47%
(95% CI 1.05% to 1.89%) at age 13, 2.22% (1.67%
to 2.78%) at age 16 and 2.99% (2.24% to 3.75%) at
age 18. Among adolescents with CDF of 6 months
duration at 13 years 75.3% (64.0% to 86.6%) were not
classiﬁed as such at age 16. Similar change was
observed between 16 and 18 years (75.0% (62.8% to
87.2%)). Of those with CDF at age 13, 8.02% (0.61%
to 15.4%) presented with CDF throughout the duration
of adolescence.
Conclusions The prevalence of CDF lasting 6 months
or longer (a proxy for clinically diagnosed CFS/ME)
increases from 13 to 18 years. However, persistent CDF
is rare in adolescents, with approximately 75%
recovering after 2–3 years.
INTRODUCTION
Chronic fatigue syndrome/myalgic encephalomyeli-
tis (CFS/ME) is relatively common (prevalence
0.5–3%) and disabling in children and adoles-
cents.1–4 The disease has been deﬁned by various
criteria.5
In the UK, National Institute for Health and
Care Excellence (NICE) guidelines state that diag-
nosis of CFS/ME should be made in children after
3 months of persistent or recurrent fatigue, which
is not the result of ongoing exertion, not substan-
tially alleviated by rest, has resulted in a substantial
reduction in activities, is characterised by post-
exertional malaise, the presence of at least one
recognised symptom and has no known cause.6
The most commonly used research criteria (Centers
for Disease Control and Prevention (CDC)) require
6 months duration of fatigue, which has
signiﬁcantly interfered with daily activities, and the
individual must have four or more recognised
symptoms of CFS/ME.7
CFS/ME has a signiﬁcant impact on an adoles-
cent’s education, family and social life. Children
attending specialist (secondary care) services
attend, on average, 2 days a week of school.8
Two thirds are unable to attend school at all when
the condition is at its most severe, with an average
total absence from school of 1 year (at 4 years
follow-up).9 10 Most children (96%) stop socialis-
ing with their friends10 and there are emotional
and ﬁnancial consequences for families.11
Understanding the prognosis of this condition in
children and adolescents is therefore vital.
However, little is known about the persistence of,
or recovery from, CFS/ME in adolescence.
A systematic review of observational studies
reported that 50–94% of adolescents made a
good or complete recovery at 13–72 months.12
However, the sample sizes included in this review
were small (median=78; range=15–498), the dur-
ation of symptoms at outset and length of
follow-up were highly variable, and it only
included participants accessing secondary or ter-
tiary care. More recently, a small number of obser-
vational studies have been conducted, which
followed adolescents with CFS/ME recruited into
specialist services, that revealed less favourable
recovery rates of 40–70%.9 13 14 15 It is therefore
What is already known on this topic?
Chronic fatigue syndrome/myalgic
encephalomyelitis (CFS/ME) is relatively common
and disabling in children and adolescents. Previous
studies (typically with small samples) have
reported inconsistent estimates of persistence of
CFS/ME during adolescence. The long-term
prognosis of the condition in those not receiving
treatment is not known.
What this study adds?
The prevalence of chronic disabling fatigue (CDF),
a proxy for clinically diagnosed CFS/ME, increases
during adolescence. Approximately 25% persist
over a 2–3-year follow-up. Only 8% of children
with CDF at age 13 had CDF at 16 and 18 years.
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difﬁcult to say with any certainty what proportion of adoles-
cents who do not receive treatment will recover and what pro-
portion will have persistent fatigue. Furthermore, the extent to
which CFS/ME in early adolescence increases the risk of devel-
oping CFS/ME in later adolescence is unknown.
The aim of this study was to describe the prevalence of
CFS/ME at 18 years and the persistence and recovery of
CFS/ME during adolescence. By deﬁning persistent fatigue using
a 6 months criterion, we aimed to compare persistence and
recovery consistent with the widely used CDC diagnostic criteria
for CFS/ME.7 16 However, results based on a 3-month criterion
of fatigue duration, in line with the NICE diagnostic criteria,
will also be presented in the online supplementary material. As
children in our study were not examined by a physician, we have
used the term ‘chronic disabling fatigue’ (CDF) rather than
CFS/ME to indicate chronic fatigue that is disabling.
METHODS
Sample
The Avon Longitudinal Study of Parents and Children (ALSPAC)
is a population-based longitudinal birth cohort of children who
had an expected date of delivery between April 1991 and
December 1992 and whose mothers were resident in the Avon
region of Southwest England at the time of recruitment.17 From
14 541 pregnancies included, 13 978 children were alive at
12 months of age (excluding triplets and quadruplets). The chil-
dren have been followed up regularly since birth with postal
questionnaires for both children and their parents, clinical
assessments and the collection of biological samples (please
note that the study website contains details of all the data that is
available through a fully searchable data dictionary: http://www.
bris.ac.uk/alspac/researchers/data-access/data-dictionary/).
Figure 1 shows the available data at each time point and the
number of cases classiﬁed with CDF.
Variables
CDF at age 13 years
Our method for deﬁning CDF at age 13 years has been
described previously.1 In brief, we identiﬁed adolescents
reported by their mothers to have experienced fatigue lasting
>6 months that was associated with absence from full-time
school or that had prevented them from taking part in activities
‘quite a lot’ or ‘a great deal’. We excluded those whose mothers
thought that the fatigue was caused by playing too much sport,
who snored often and who had other illnesses that could cause
fatigue (based on self-reported medication use). Adolescents
were assigned a missing value for CDF if the question for
school attendance had not been answered.
CDF at age 16 years
Our method for deﬁning CDF at age 16 years has been
described previously.18 Brieﬂy, a classiﬁcation of CDF was based
on both parental and child-reported data. We classiﬁed adoles-
cents as chronically fatigued if parents had reported that they
had fatigue lasting >6 months that had stopped them from
taking part in activities ‘quite a lot’ or ‘a great deal’, that was
not due to playing too much sport and that had resulted in any
absence from school/college in the past year due to tiredness or
Figure 1 Flowchart showing number of subjects with available information in each age and those with chronic disabling fatigue. ALSPAC, Avon
Longitudinal Study of Parents and Children.
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lack of energy. The child reported data that was used in order to
classify CDF was based on the Chalder Fatigue Questionnaire,19
with a score of ≥19 (out of 33) representing CDF. A cut-off
score of 19/33 has a sensitivity of 82.4% and a speciﬁcity of
86.4% for CFS/ME in adolescence.20 Teenagers were classiﬁed
as non-CDF if the parent had provided answers indicating CDF
but the Chalder score was <19. Furthermore, teenagers were
classiﬁed as having CDF if they met the criteria by parental
report but Chalder fatigue data were missing, under the assump-
tion that teenagers with CDF would be less likely to have com-
pleted the ‘Life of a 16+ teenager’ questionnaire.
CDF at age 18 years
At age 17/18 (median 17.8, IQR 17.6 to 17.9) years, adoles-
cents attended a ‘Focus @ 17’ clinic, at which they completed a
computer-based Revised Clinical Interview Schedule (CIS-R).21
Participants were classiﬁed as CDF if they indicated that they
had been getting tired or had been lacking in energy during the
past month and then responded ‘yes’ to >2 of the following
four items: (1) felt tired or lacking in energy for 4 days or more
in the past seven days; (2) felt tired or lacking in energy for
more than 3 hours in total on any day in the past seven days;
(3) felt so tired or lacking in energy that they had to push them-
selves to get things done on one or more occasion in the past
seven days and (4) felt tired or lacking in energy when doing
things they enjoy in the past seven days.
We classiﬁed the following as not CDF: the tiredness or lack
of energy had lasted for <6 months; the adolescent thought it
was due to exercise or medication; the adolescent felt better
after resting or if exercise did not make them feel exhausted the
following day. The CIS-R also provided data on seven of the
eight symptoms of CFS/ME speciﬁed in CDC diagnostic cri-
teria,7 namely muscle or joint pain, headaches, painful glands,
sore throat, problems with memory or concentration (cognitive
dysfunction) and insomnia (as a proxy for ‘unrefreshing sleep’).
We required the presence of at least one of these symptoms,
rather than the minimum of four required by CDC criteria, as
this is consistent with UK guidance for the diagnosis of CFS/
ME. Adolescents were classiﬁed as not having CDF if they
reported having had problems with alcohol or drugs (crack, sol-
vents, heroin or cocaine) during the previous year or a diagnosis
of anorexia nervosa.
At all three time points, the presence of comorbid depressive
symptoms was not an exclusion criteria for the classiﬁcation of
CDF, but sensitivity analyses excluding those with signiﬁcant
depressive symptoms (≥11 on the Short Moods and Feelings
questionnaire (SMFQ))22 were conducted. The SMFQ correlates
well with other measures of depression and has good test–retest
reliability.23 24 A cut-off score of ≥11 was used to indicate high
levels of depressive symptoms, a threshold that has shown high
sensitivity, speciﬁcity and negative predictive power for an
International Classiﬁcation of Disease-10 diagnosis of depres-
sion at age 18 years in this cohort.25
Statistical analysis
First, the crude prevalence of CDF, using a criterion of at least
6 months, was estimated at each time point among those adoles-
cents for whom sufﬁcient data were available to deﬁne its pres-
ence or absence.
Recovery/persistence from CDF
Subjects with CDF at one time point (age 13 or age 16) were
categorised as having persistent CDF across two time points
(13–16 or 16–18) if they were also classiﬁed as having CDF at
the next time point, otherwise classiﬁed as recovered.
Multiple imputation to address missing data
Performing only complete-case analyses (ie, ignoring those ado-
lescents with missing values for CDF or covariates) could result
in bias and would result in inﬂation of SEs. If missingness is
dependent only on observed data (referred to as missing at
random), then multiple imputation can be used to correct this
bias. We generated 90 imputed data sets based on a set of vari-
ables that were selected because of either their strong hypothe-
sised association with CDF, the relatedness to the missingness of
CDF and/or the amount of missing data in these variables them-
selves (considered in order to construct stable imputation
models that would produce reliable estimates). These included
fatigue (measured at 13, 16 and 18 years), maternal age at deliv-
ery, maternal education, total family adversity index (FAI) score
recorded during pregnancy (representing multiple indicators of
family, parental and sociodemographic risk), total FAI score
recorded when the child was 8–10 years old, three additional
components of the FAI recorded at 8–10 years, total authorised
absences during year 11 of schooling, total unauthorised
absences during year 11 of schooling, mean Key Stage 2 mark
and total score on the Strength and Difﬁculties Questionnaire
measured when the child was 11 (descriptions of these are pro-
vided in the online supplementary material). The number of
imputations required to achieve convergence of parameter esti-
mates was determined by checking the estimate of the Monte
Carlo error (MCerror) in relation to the SE of the coefﬁcient
being estimated. In particular, the number of imputations was
increased incrementally and when the MCerror achieved a value
that was <10% of the SE of the estimate, the number of impu-
tations was deemed adequate. The sample after imputation was
13 978, which represents those who were in the ‘core’ ALSPAC
sample, who were alive at 1 year and who were either a single-
ton or twin. Multivariable imputation was performed using the
univariate chained equations method paired with regression
switching26 (using Stata’s user-written ‘ice’ command), combin-
ing estimates using Rubin’s rules.27
Whereas the prevalence of CDF at 18 was calculated in the
both the complete case and imputed data sets, the persistence
and recovery will only report on the imputed estimates, to
provide less biased estimates of the persistence and recovery
(complete case results included in the online supplementary
material). Imputed estimates were rounded to the nearest
integer to aid interpretability. Analyses were performed using
Stata V.13.1 (StataCorp. 2013. College Station, Texas, USA:
StataCorp LP).
RESULTS
Data necessary for a classiﬁcation of CDF were available for
6720 adolescents at 13 years, 5756 at 16 years and 4290 at
18 years. Table 1 shows that those with missing fatigue data
were more likely to be male, have a higher FAI (at 8–10 years),
have depressive symptoms at 18.6 years and were less likely to
apply to university.
In those with enough data to make a classiﬁcation of CDF,
adolescents with CDF were more likely to be female, have
higher levels of family adversity (at age 8–10) and more likely
to have depressive symptoms at 18.6 years compared with those
without CDF. Online supplementary table S1 displays the distri-
bution of, and amount of data for, the imputed variables in
those in the complete case analysis.
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Prevalence at 18
At age 18 years, 2.40% (103/4290) were classiﬁed as having
CDF lasting 6 months or longer (95% CI 1.98 to 2.90), with
29.1% (95% CI 21.1% to 38.7%) of these fulﬁlling the CDC
criteria (four or more symptoms, 6 months fatigue), while
100% fulﬁlled the NICE criteria of ≥1 symptom. The previ-
ously reported higher 16-year prevalence observed in females
persisted at 18 (76/2413, 3.15%; 95% CI 2.52% to 3.93%)
compared with males (n=27/1877, 1.44%; 95% CI 0.99% to
2.09% (difference=1.71%; 95% CI 0.83 to 2.59, p<0.001)).
Imputed 18-year estimates revealed a prevalence of 2.99%
(95% CI 2.24% to 3.75%), with the sex difference persisting
(females: 3.58%; 95% CI 2.74 to 4.42%; males: 2.44%; 95%
CI 1.25% to 3.63%).
Of those who had both CDF at 18 years and available depres-
sion data, 40% (20/50) had depressive symptoms. If all those
with any depressive symptoms during adolescence (13, 16 or
18 years) were recoded to non-CDF, the prevalence of CDF at
18 was 1.21% (95% CI 0.92% to 1.59%). This increased to
2.17% after imputation.
Online supplementary table S2 shows the prevalence esti-
mates for CDF at 13 and 16 years, using both the 3-month and
6-month criteria.
Recovery from/persistence of CDF
Between 13 and 16 years, imputation revealed that 24.7% (95%
CI 13.5% to 36.0%) of those with CDF at 13 also had CDF at
16 years (ﬁgure 2). A small percentage of the adolescents who
had CDF at 13 also had it at 18 but not 16 (5.75% (95% CI
2.52% to 14.0%)). Between 16 and 18 years, 25.0% (95% CI
12.8 to 37.2%) of those with CDF at 16 also had CDF at
18 years. Finally, 8.02% (95% CI 0.61% to 15.4%) of adoles-
cents with CDF at 13 maintained this classiﬁcation at all three
time points (tables 2 and 3 show the presence of CDF at later
time points by presence of earlier CDF).
Sensitivity analyses reclassifying those with CDF and any
depressive symptoms during adolescence to non-CDF suggested
that persistence between 13 and 16 years was similar (13–
16 years: 24.2%; 95% CI 12.7% and 35.7%), but with reduced
persistence between 16 and 18 years (18.5%; 95% CI 7.53%
and 29.6%), and between all three time points (5.71%; 95% CI
0.71% and 12.13%).
Online supplementary table S3 shows presence of CDF at
later time points by the presence of earlier CDF, deﬁned using
the 3-month fatigue criterion.
DISCUSSION
We have shown that, in a large cohort of adolescents, the preva-
lence of CDF increased with advancing age, so that, using
imputed results, 1.47% (95% CI 1.05% to 1.89%) of adoles-
cents had the condition at 13, increasing to 2.22% (95% CI
1.67% to 2.78%) at 16 years and 2.99% (95% CI 2.24% to
3.75%) at 18 years. Approximately 25% of adolescents showed
persistence of CDF at the subsequent time point, which was 2
(16–18) or 3 (13–16) years later. 8.02% of those classiﬁed as
having the condition at 13 would still have the condition at 16
and 18, suggesting that they probably had CDF throughout
adolescence.
Comparison with other studies
The proportion of children in our study with CDF at age 13 that
persisted at age 16 was 24.7% (95% CI 13.5% to 36.0%), with
a similar ﬁgure also observed between 16 and 18 years (25.0%;
95% CI 12.8 to 37.2%). This is slightly lower than that
described in observational studies on clinic populations. Smith
et al28 observed that, in a sample of 15 adolescents, CFS/ME
had either persisted or worsened in 46.7% (by self-report) at
follow-up 12–32 months later. Rangel et al9 followed 25 adoles-
cents for 46 months and observed no improvement, or worsen-
ing of symptoms, in 32%. Similar persistence was observed at
3–4 years follow-up by Gill et al13 (44%) and Sankey et al14
(33.3%). Bell et al29 conducted a follow-up study of 35 adoles-
cents, with an average follow-up of 13 years (average age at
illness onset: 12.1 years). Compared with the aforementioned
studies, persistence after this extended period of follow-up was
lower, with only approximately 20% reporting being either as or
more ill than at the study onset. Our lower persistence may
reﬂect less severe disease in the population compared with clin-
ical cohorts. We observed a group of adolescents (8.02%; 95%
CI 0.61% to 15.4%) who were classiﬁed as CDF at all three
time points. These adolescents may represent a group who were
experiencing a more severe form of the disease, characterised by
increased persistence or recurrence of the disease.
Our ﬁnding that CDF is more common in females at age 18 is
consistent with a number of other studies in adolescence.2 30–32
Indeed in this cohort, 16-year-old females had a similarly
Table 1 Descriptive statistics for those with chronic disabling fatigue (CDF) at 18, those without CDF and those with missing data
Data on fatigue (n=4290)
Missing fatigue
data (n=9688) p Value‡CDF (n=103) Not CDF (n=4187) p Value*† Total
Sex (male) 27/103 (26%) 1850/4187 (44.2%) <0.001 1877/4290 (43.8%) 5343/9688 (55.2%) <0.001
FAI at 8–10 years (range 0–14) 1.39 (1.06–1.71) 0.98 (0.94–1.03) 0.005 0.99 (0.95–1.03) 1.11 (1.07–1.51) <0.001
Number of AS levels obtained# 3.49 (3.09–3.88) 3.52 (3.46–3.58) 0.88 3.52 (3.46–3.58) 3.51 (3.41–3.60) 0.82
Number of A-levels studying# 2.69 (2.18–3.21) 2.83 (2.75–2.91) 0.54 2.83 (2.75–2.91) 2.85 (2.73–2.96) 0.76
Depression at 18 (yes) 20/50 (40%) 421/2158 (19.5%) <0.001 441/2208 (20.0%) 248/985 (25.2%) 0.001
Applied to university (yes) 29/50 (58%) 1324/2158 (61.4%) 0.63 1353/2208 (61.3%) 490/990 (49.5%) <0.001
Currently has a paid job (yes) 26/46 (57%) 1309/1955 (67.0%) 0.14 1335/2001 (66.7%) 563/880 (64.0%) 0.153
Number of CFS/ME symptoms (≥4) (CDC criteria) 30/103 (29%) 218/4187 (5.2%) <0.001 248/4290 (5.8%) – –
*χ2 tests for proportions, t-tests for means.
†CDF versus not CDF.
#AS level: Advanced Subsidiary Level taken at 17 years A level: General Certificate of Education Advanced Level taken at 18 years.
‡Fatigue data versus missing fatigue data.
CDC, Centers for Disease Control and Prevention; CFS/ME, chronic fatigue syndrome/myalgic encephalomyelitis; FAI, Family adversity index.
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increased risk (OR 1.64 (1.00 to 2.70)).18 However, this is dif-
ferent to 13 year olds and primary school children where the
prevalence has been observed to be equal in males and
females.1 31 This might be because of changing cortisol proﬁle
in females,33 or hormonal sex differences that arise during
puberty, for example, testosterone, which has been shown to
help prevent muscle fatigue34 and thus could contribute to this
sex difference.35 Gender differences in coping strategies may be
Figure 2 Proportion (SE) of those showing recovery from/persistence of chronic disabling fatigue (CDF) between 13 and 18 years old, after multiple
imputation of missing data.
Table 2 Presence of chronic disabling fatigue (CDF) in total






CDF at age 16 CDF at 13 51/206 (24.7%) 16.8 (8.4–33.8)
No CDF at 13 260/13 772 (1.9%)
CDF age 18 CDF at 16 78/311 (25.0%) 12.9 (6.4–26.1)
No CDF at 16 340/13 667 (2.5%)
CDF at 13, CDF at 16 17/51 (33.3%) 7.9 (3.2–19.3)
CDF at 13, no CDF
at 16
9/155 (5.8%)
No CDF at 13, CDF
at 16
61/260 (23.5%) 12.1 (5.7–25.6)
No CDF at 13, no CDF
at 16
331/13 512 (2.5%)
*Imputations based on previous CDF, maternal age at delivery, maternal education,
total family index score recorded during pregnancy, total family adversity index (FAI)
score recorded when the child was 8–10 years old, three additional components of
the FAI recorded at 8–10 years, total authorised absences during year 11 of
schooling, total unauthorised absences during year 11 of schooling, mean Key Stage
2 mark and total score on the Strength and Difficulties Questionnaire measured when
the child was 11.
Table 3 Presence of chronic disabling fatigue (CDF) in males and







CDF at age 16 CDF at 13 30/119 (25.2%) 19.7 (7.4–52.7)
No CDF at 13 117/7101 (1.6%)
CDF at age 18 CDF at 16 38/147 (25.9%) 17.1 (5.0–58.6)
No CDF at 16 139/7073 (2.0%)
Girls
CDF at age 16 CDF at 13 21/86 (24.4%) 14.2 (5.0–39.8)
No CDF at 13 143/6672 (2.1%)
CDF at age 18 CDF at 16 40/165 (24.2%) 10.0 (4.3–23.4)
No CDF at 16 202/6593 (3.1%)
*Imputations based on previous CDF, maternal age at delivery, maternal education,
total family index score recorded during pregnancy, total family adversity index (FAI)
score recorded when the child was 8–10 years old, three additional components of
the FAI recorded at 8–10 years, total authorised absences during year 11 of
schooling, total unauthorised absences during year 11 of schooling, mean Key Stage
2 mark and total score on the Strength and Difficulties Questionnaire measured when
the child was 11.
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implicated, with females reportedly displaying more negative
coping strategies during adolescence,36 or females may experi-
ence a disproportionate amount of stressful events during
adolescence.37
Strengths and limitations
This is, to our knowledge, the largest study with the longest
follow-up to have investigated the persistence and recovery of
CDF in adolescence. Furthermore, as we have deﬁned CDF
using a 6-month criterion and adopted a number of exclusion-
ary criteria used in the classiﬁcation of CFS/ME, we have pro-
duced estimates that are comparable with the widely used CDC
deﬁnition of CFS/ME, albeit with more relaxed criteria regard-
ing the number of symptoms required to be present (one rather
than four).
As is commonly observed in longitudinal studies, loss to
follow-up was apparent in our study, with increasing amounts of
missingness with advancing age. However, the use of multiple
imputation enabled the analysis to be conducted on the
maximal sample size and thus increase precision in the estimates
and correct for potential bias in prevalence estimates caused by
differential losses to follow-up. As imputed estimates were
higher than those derived from complete data, this suggests that
adolescents who were lost to follow-up were more likely to have
risk factors that are positively associated with CDF. Imputations
were based on variables that were predictive of the pattern of
missingness in CDF, or predictive of CDF itself, but which did
not have substantial amounts of missing data (<50%). This deci-
sion was made because prior results from models including vari-
ables that had substantial amounts of missing data (>70%)
produced unstable estimates for the prevalence of CDF.
However, it is acknowledged that this approach may have led to
variables with strong hypothesised associations with CDF being
omitted from the imputation models.
The main limitation of the study is that our classiﬁcation is
based on a combination of self-report of symptoms experienced
by the adolescents and by parental report, with no diagnosis
conﬁrmed by a paediatrician. We therefore cannot rule out that
other diagnoses could have been present that explained the
fatigue. However, the exclusion criteria employed, including
those on medication, those who reported having had problems
with alcohol or drugs in the previous year or received a diagno-
sis of anorexia nervosa, means we are likely to have excluded
such conditions.
Due to differential availability of relevant data at the three
measurement occasions, the criteria used to classify adolescents
as CDF were different at 13, 16 and 18. For example, classiﬁca-
tions at 13 were based on parental report, with both parental
and child-reported data used at 16, and exclusively child-
reported data at 18. We acknowledge the limitation of different
reporting methods and that this may lead to slight inconsisten-
cies in the prevalence estimates, with studies reporting differing
prevalence estimates depending on whether report was done by
parent or child or both.18 38 We are conﬁdent that our deﬁni-
tions provided a consistent classiﬁcation of CDF across the dif-
ferent ages, which is supported to some degree by our observed
prevalences being consistent with other studies in children and
adolescents. At age 16, our deﬁnition was based on
parent-reported and child-reported data, including a Chalder
Fatigue Questionnaire threshold, which has a sensitivity of 82%
and a speciﬁcity of 86% for CFS/ME.
We included adolescents with both CDF and depressive symp-
toms. Approximately 30% of children with CFS/ME in specialist
services have comorbid depression, and it is not known whether
this is a predictor of, or secondary to, CFS/ME.39 If depression
is secondary to CDF, then by reclassifying those with depression
as non-CDF, we would have underestimated prevalence esti-
mates for CDF.
Finally, as we did not have data on whether the adolescents
were receiving specialist treatment or not, we are unable to
accurately deﬁne the ‘natural course’ of CDF during this period.
However, data were collected before there was a specialist
service available in Bristol, and therefore, it is unlikely that chil-
dren received specialist treatment.
CONCLUSION
In this large cohort of adolescents, the prevalence of CDF (a
proxy for clinically diagnosed CFS/ME) increases throughout
adolescence, with 2.99% (95% CI 2.24% to 3.75%) of 18 year
olds classiﬁed as such. Despite this increasing prevalence, we
have shown that approximately three quarters of adolescents
recovered from a previous classiﬁcation of CDF, with around
8% of those classiﬁed as having CDF at the beginning of adoles-
cence persisting with the condition at both 16 and 18 years.
These ﬁndings should be interpreted within the limitations of
the study, most notably the different deﬁnitions of CDF at the
three time points.
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